National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892, United States
NCT Number: NCT00001324
Positron Emission Tomography (PET) is a technique used to investigate activity in areas of the brain. The PET technique allows researchers to study the normal processes in the brain (central nervous system) of normal individuals and patients with neurologic illnesses without physical / structural damage to the brain.
When a region of the brain is active, it uses more fuel in the form of oxygen and sugar (glucose). As the brain uses more fuel it produces more waste products, carbon dioxide and water. Blood carries fuel to the brain and waste products away from the brain. As brain activity increases, blood flow to and from the area of activity also increases. This is known as regional cerebral blood flow (rCBF). Knowing these facts, researchers can use radioactive water (H215O) and PET scans to observe what areas of the brain are receiving more blood flow.
In this study researchers plan to investigate the changes in regional cerebral blood flow (rCBF) as patients participate in different activities. The activities are designed to stimulate the areas of the brain responsible for voluntary motor activity and sensation. By comparing the results of PET scans performed in different conditions, researchers can locate regions of the brain responsible for specific tasks.
This study should provide new information about voluntary movements in humans and the preparation involved in controlling them.
Looking for future studies?
Notify MeAll sexes
Observational
Bethesda, Maryland, 20892, United States
The main purpose of the studies presented in this protocol is to investigate the physiology of motor control in health as well as the pathophysiological modifications taking place during disease. To this end, we will investigate changes in regional cerebral blood flow (rCBF) as an index of regional neuronal activity, associated with various motor and sensory tasks using Positron Emission Tomography (PET). The rCBF will be obtained by measuring the distribution of the cerebral radioactivity during emission scans following the intravenous bolus injection of 15O-labeled water. The very short half-life of 15O (2 minutes) allows us to measure rCBF repeatedly under different task conditions (see methodology and experimental procedures). With the comparison between PET scans performed in different conditions, we can detect the specific task-related activated regions. PET images will be coregistered to high resolution Magnetic Resonance Images (MRI) to get more accurate anatomical information regarding the activated areas. The results will be correlated with that from other physiological approaches including Electroencephalography (EEG), Transcranial Magnetic Stimulation (TMS), functional Magnetic Resonance Imaging (fMRI), and Magnetic Resonance Spectroscopy (MRS). These studies should provide new information not only about the executive component of the voluntary movements in humans but also the different organizational aspects of the preparatory processes that control them.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Patients with movement disorder and normal volunteers.
National Institute of Neurological Disorders and Stroke (NINDS)
Nih
CNS Control of Human Movement: H215O PET Studies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06617884
Ataxia, Basal Ganglia Diseases
Düsseldorf, North Rhine-Westphalia, Germany
View Trial DetailsNCT05680571
Ataxia, Basal Ganglia Diseases
Oslo, Norway
View Trial DetailsNCT03722212
Ataxia, Central Nervous System Diseases
Angers, France
View Trial DetailsNCT06585605
Ataxia, Brain Diseases
Boston, Massachusetts, United States
View Trial Details